Activity of Imipenem-Relebactam and Meropenem-Vaborbactam against Carbapenem-Resistant, SME-Producing Serratia marcescens
Mark Biagi, Aisha Shajee, A. Vialichka, M. Jurkovic, X. Tan, Eric Wenzler
Abstract
enzyme (SME) is a chromosomally encoded carbapenemase with no known optimal treatment. Various β-lactam/β-lactamase inhibitors and comparators were evaluated against 8 SME producers via broth microdilution. Four isolates were subsequently tested via time-kill analyses. All isolates were resistant to imipenem, imipenem-relebactam, and meropenem but susceptible to ceftazidime, ceftazidime-avibactam, and meropenem-vaborbactam. Ceftazidime, imipenem-relebactam, and meropenem-vaborbactam were bactericidal against 3, 0, and 4 isolates, respectively. Meropenem-vaborbactam may be a potential option for severe SME-producing infections.
Topics & Concepts
Serratia marcescensMeropenemCeftazidime/avibactamMicrobiologyImipenemCarbapenemBroth microdilutionCeftazidimeEnterobacteriaceaeSerratiaAntibacterial agentBiologyMedicineAntibioticsBacteriaAntibiotic resistanceMinimum inhibitory concentrationEscherichia coliPseudomonas aeruginosaPseudomonasGeneGeneticsBiochemistryAntibiotic Resistance in BacteriaVibrio bacteria research studiesPharmaceutical and Antibiotic Environmental Impacts